Drug-Drug Interaction (DDI) Study of Leramistat in Healthy Adult Subjects

Last updated: August 8, 2024
Sponsor: Modern Biosciences Ltd
Overall Status: Active - Recruiting

Phase

1

Condition

N/A

Treatment

Itraconazole 200 mg

Phenytoin 100 Mg Oral Capsule

leramistat 40mg

Clinical Study ID

NCT06379958
IST-05
  • Ages 18-55
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

A DDI study consisting of 4 parts conducted as an open label, fixed sequence study in healthy adult subjects.

Eligibility Criteria

Inclusion

Principal Inclusion Criteria:

Healthy, adult, male or female of non childbearing potential 18 to 55 years of age.

Exclusion

Principal Exclusion Criteria:

History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.

History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study.

Study Design

Total Participants: 48
Treatment Group(s): 5
Primary Treatment: Itraconazole 200 mg
Phase: 1
Study Start date:
April 08, 2024
Estimated Completion Date:
September 30, 2024

Connect with a study center

  • Celerion

    Belfast,
    United Kingdom

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.